Shandong New Time Pharmaceutical Co., Ltd., commonly referred to as New Time Pharma, is a leading player in the pharmaceutical industry, headquartered in Shandong, China. Established in 2003, the company has rapidly expanded its operations across various regions, focusing on the development and manufacturing of high-quality pharmaceutical products. Specialising in active pharmaceutical ingredients (APIs) and finished dosage forms, New Time Pharma is renowned for its commitment to innovation and quality. The company’s core offerings include a diverse range of generic medications and specialty pharmaceuticals, distinguished by their efficacy and safety profiles. With a strong market presence, Shandong New Time Pharmaceutical has achieved significant milestones, including certifications from international regulatory bodies, which underscore its dedication to maintaining the highest industry standards. As a trusted partner in healthcare, New Time Pharma continues to contribute to global health advancements through its cutting-edge solutions.
How does Shandong New Time Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Shandong New Time Pharmaceutical Co., Ltd.'s score of 20 is lower than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shandong New Time Pharmaceutical Co., Ltd., headquartered in China (CN), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As there are no emissions data or reduction initiatives available, it is unclear how Shandong New Time Pharmaceutical aligns with industry standards for climate action. The absence of specific targets or commitments may reflect a broader trend within the pharmaceutical sector, where companies are increasingly being called upon to disclose their environmental impact and set ambitious goals for emissions reduction. In summary, Shandong New Time Pharmaceutical Co., Ltd. currently lacks publicly available emissions data and defined climate commitments, positioning it in a context where many industry peers are actively pursuing sustainability initiatives.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shandong New Time Pharmaceutical Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
